Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Analytical performance an… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

Artikel i vetenskaplig tidskrift
Författare Hugo Vanderstichele
Karen De Vreese
Kaj Blennow
Niels Andreasen
Christian Sindic
Adrian Ivanoiu
Harald Hampel
Katharina Bürger
Lucilla Parnetti
Alessia Lanari
Allesandro Padovani
Monica DiLuca
Miriam Bläser
Annika Öhrfelt Olsson
Hans Pottel
Frank Hulstaert
Eugeen Vanmechelen
Publicerad i Clinical chemistry and laboratory medicine : CCLM / FESCC
Volym 44
Nummer/häfte 12
Sidor 1472-80
ISSN 1434-6621
Publiceringsår 2006
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 1472-80
Språk en
Länkar dx.doi.org/10.1515/CCLM.2006.258
Ämnesord Aged, Alzheimer Disease, diagnosis, Amyloid beta-Protein, cerebrospinal fluid, Biological Markers, cerebrospinal fluid, Diagnosis, Differential, Discriminant Analysis, Enzyme-Linked Immunosorbent Assay, methods, Female, Humans, Lewy Body Disease, diagnosis, Logistic Models, Male, Middle Aged, Peptide Fragments, cerebrospinal fluid, Phosphothreonine, metabolism, ROC Curve, Reagent Kits, Diagnostic, standards, Reproducibility of Results, Sensitivity and Specificity, tau Proteins, cerebrospinal fluid, metabolism
Ämneskategorier Neurokemi

Sammanfattning

BACKGROUND: Total tau (T-tau) and beta-amyloid((1-42)) (Abeta(1-42)) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult. METHODS: The analytical performance of the INNOTEST PHOSPHO-TAU(181P) assay was validated in terms of selectivity, sensitivity, specificity, precision, robustness, and stability. Clinical utility of the assay alone, or combined with T-tau and Abeta(1-42), for discrimination of AD (n=94) from patients suffering from DLB (n=60) or from age-matched control subjects (CS) (n=60) was assessed in a multicenter study. RESULTS: CSF concentrations of tau phosphorylated at threonine 181 (P-tau(181P)) in AD was significantly higher than in DLB and CS. Discriminant analysis, a classification tree, and logistic regression showed that P-tau(181P) was the most statistically significant single variable of the three biomarkers for discrimination between AD and DLB. CONCLUSIONS: P-tau(181P) quantification is a robust and reliable assay that may be useful in discriminating AD from DLB.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?